

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.9294 - BMS / CELGENE**

**SECTION 1.2**

**Description of the concentration**

1. The notified concentration concerns the acquisition by Bristol-Myers Squibb Company of Celgene Corporation in a cash and stock transaction with an equity value of approximately USD 74 billion.
2. BMS is a global biopharmaceutical company engaged in the development and commercialisation of innovative medicines for the treatment of patients with serious diseases. BMS has activities in four main therapeutic areas: oncology; immunoscience (which includes autoimmune diseases); cardiovascular diseases; and fibrotic diseases. BMS is headquartered in New York (USA) and is listed on the New York Stock Exchange.
3. Celgene is an integrated global biopharmaceutical company engaged primarily in the development and commercialisation of innovative therapies for treating cancer and inflammatory diseases (which includes autoimmune diseases). Celgene is headquartered in New Jersey (USA) and is listed on the Nasdaq Stock Market.